P2Y12 inhibitors (drug class)
P2Y12 inhibitors are antiplatelet medicines that act on the P2Y12 receptor of platelets. The US labels of ticagrelor, clopidogrel and prasugrel, the three members recorded in this atlas so far, put each in this class. The labels say each medicine prevents platelet activation by acting on the platelet receptor: ticagrelor reversibly, and clopidogrel and prasugrel through the irreversible binding of an active metabolite. This is the class page: what each medicine has been shown to do sits on its own page.
Also called P2Y12 Platelet Inhibitor · P2Y12 Receptor Antagonists
- Drug
- In this atlas
Overview
Technical summary
US drug-label classes in RxClass for ticagrelor: established pharmacologic class P2Y12 Platelet Inhibitor (EPC) and mechanism-of-action class P2Y12 Receptor Antagonists (MOA). No MeSH heading is recorded for the class, because none was looked up for it; the identifiers list is empty for that reason. The label writes the class name with a space (P2Y 12). Clopidogrel and prasugrel carry the same two RxClass classes in the labels read. The class names are recorded from the RxClass responses of 2026-10-30 (ticagrelor) and 2026-11-09 (clopidogrel, prasugrel).
Trials at a glance
The figures count the 72 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 72
- Phase 3 or 4
- 63
- Recruiting
- 4
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 1 | 4 | 0 | 1 | 6 |
| Phase 2/3 | 0 | 3 | 0 | 0 | 3 |
| Phase 3 | 1 | 12 | 1 | 3 | 17 |
| Phase 4 | 2 | 28 | 3 | 13 | 46 |
| All phases | 4 | 47 | 4 | 17 | 72 |
Conditions these trials study
- Acute coronary syndrome
- Coronary artery disease
- Heart attack (myocardial infarction)
- ST-elevation heart attack (STEMI)
- Stroke
- Ischemic stroke
- Angina pectoris
- Diabetes mellitus
- Chronic kidney disease (CKD)
- Non-ST-elevation heart attack (NSTEMI)
Sponsors with the most trials
Drugs in this class
3 drugs in this atlas are filed under P2Y12 inhibitors (drug class), with the registry trials and FDA regulatory decisions this atlas holds for each. With P2Y12 inhibitors (drug class) itself, the class has 157 distinct trials and 14 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- The US drug-label established pharmacologic class for ticagrelor in RxClass is P2Y12 Platelet Inhibitor, and its mechanism-of-action class is P2Y12 Receptor Antagonists.
Claims and evidence
No claims are published for this drug yet.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 72
Record details
- Record id
cardio:p2y12-inhibitors- Content hash
511663dfa47f129ae08ae8af2ceecd96996467425b34b73db8e6661c2f8a6eba